ADC Therapeutics
Discontinuation of LOTIS-9 Trial: Zynlonta in Unfit DLBCL Patients
SG Tylor
Source – ADC Therapeutics On July 20, 2023, ADC Therapeutics announced its decision to discontinue the Phase II LOTIS-9 clinical ...
After 7 patient fatalities and 5 other serious adverse events, ADC suspends the Zynlonta research
SG Tylor
Source – ADC Therapeutics ADC Therapeutics has halted enrollment in a Phase II combination trial for Zynlonta following the investigation ...
